Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
How RFK Jr's war on obesity in the age of Ozempic could shake up the booming weight-loss industry
Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...
Heard on the Street Monday Recap: RFK Bridge to Nowhere
Friday was a doozy for many biotech and pharmaceutical companies after news broke late Thursday that President-elect Donald Trump would nominate vaccine skeptic Robert F. Kennedy Jr. to the nation's ...
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential
Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.